Adverum Biotechnologies has a market capitalization of $744.08 million and generates $1.61 million in revenue each year. The biotechnology company earns $-72,630,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe. ADVM had returned +22.41% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. More Info About Adverum Biotechnologies, Inc. (ADVM) Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. 12/31/2019 · Adverum Biotechnologies, Inc. (ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that 24-week data from the first cohort of patients in the OPTIC phase 1 clinical trial of ADVM-022 intravitreal injection gene therapy in wet AMD will be presented at the Retina Subspecialty Day